Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule IV
- 0.5mg
- 1mg
- 2mg
capsule, extended-release: Schedule IV
- 1mg
- 2mg
- 3mg
oral concentrate: Schedule IV
- 2mg/mL
injectable solution: Schedule IV
- 2mg/mL
- 4mg/mL
Anxiety Disorders
Indicated for management of anxiety disorders or for the short-term relief of symptoms of anxiety or anxiety associated with depressive symptoms
Anxiety or tension associated with stress of everyday life usually does not require treatment with an anxiolytic
Efficacy in long-term use (ie, >4 months), has not been assessed by systematic clinical studies
Tablets
- Initial: 2-3 mg PO q8-12hr PRN; not to exceed 10 mg/day
- Maintenance: 2-6 mg/day PO divided q8-12hr
Extended-release capsules (Loreev XR)
- Indicated for anxiety disorders in adults who are receiving stable, evenly divided, TID dosing with lorazepam tablets
- Recommended dose: Administer capsule PO qAM; dose equals the total daily dose of previously administered lorazepam tablets
- Dosage adjustment: Discontinue Loreev XR and switch to lorazepam tablets to adjust dosage
Short-Term Treatment of Insomnia
Tablets: 2-4 mg PO qHS
Preoperative Sedation, Anxiety Relief, & Anterograde Amnesia
0.05 mg/kg IM for 1 dose; 2 hours before surgery; not to exceed 4 mg (2 mg/dose in elderly), OR
0.044 mg/kg IV for 1 dose; 15-20 minutes before surgery; not to exceed 4 mg (2 mg/dose in elderly)
Status Epilepticus
Usual 4 mg/dose slow IV at 2 mg/min
If seizure persists after 5-10 min, administer 4 mg IV again
Anxiolytic/Sedation in ICU (Off-label)
Intubated and mechanically ventilated patients
- 0.02-0.04 mg/kg loading dose IV
- 0.02-0.06 mg/kg intermittent IV q2-6hr PRN, OR
- 0.01-0.1 mg/kg/hr continuous IV; not to exceed 10 mg/hr
Chemotherapy-Induced Nausea/Vomiting (Off-label)
0.5-2 mg PO/IV q6hr; PRN thereafter
Chronic Insomnia (Off-label)
2-4 mg PO qHS
Dosing Modifications
Renal impairment
- PO: Dose adjustment not necessary
- IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment or renal failure
- IV/IM (prolonged periods or high doses): Monitor; risk of propylene glycol toxicity
Hepatic impairment
- PO: No dose adjustment recommended in mild-to-moderate impairment; use with caution (may require lower dose) in severe impairment
- IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment of hepatic failure
Dosing Considerations
Periodically reassess the usefulness for individual patients
IV: Monitor respirations q5-15min and before each repeated IV dose
Dosage Forms & Strengths
tablet: Schedule IV
- 0.5mg
- 1mg
- 2mg
oral concentrate: Schedule IV
- 2mg/mL
injectable solution: Schedule IV
- 2mg/mL
- 4mg/mL
Status Epilepticus (Off-label)
Infants and children: 0.05-0.1 mg/kg IV over 2-5 minutes; not to exceed 4 mg/dose; may repeat q10-15min PRN
Alternatively, 0.1 mg/kg at slow IV rate not to exceed rate of 2 mg/min; not to exceed dose of 4 mg
Adolescents: 4 mg slow IV; if seizure persists after 10-15 minutes, administer 4 mg IV again
Anxiolytic/Sedation/Agitation (Off-label)
Children: 0.05 mg/kg/dose PO q4-8hr; not to exceed 2 mg/dose
Chemotherapy-Induced Nausea/Vomiting (Off-label)
Children >2 years: 0.025-0.05 mg/kg/dose IV q6hr PRN; not to exceed 2 mg/dose
Dosing Considerations
IV: Monitor respirations q5-15min and before each repeated IV dose
Preferred agent in elderly because short-acting and has inactive metabolite
Anxiety disorders
Lower initial dose recommended; 1-2 mg PO divided q8-12hr
Insomnia
Lower initial dose recommended; 0.5-1 mg PO qHS, increase PRN
To avoid oversedation, initial daily dose should not exceed 2 mg
Dosing considerations
When higher dose indicated, increase evening dose before daytime doses
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (11)
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
benzhydrocodone/acetaminophen and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine subdermal implant
buprenorphine subdermal implant and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- buprenorphine transdermal
buprenorphine transdermal and lorazepam both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- calcium/magnesium/potassium/sodium oxybates
lorazepam, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- hydrocodone
hydrocodone, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- metoclopramide intranasal
lorazepam, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
lorazepam and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- selinexor
selinexor, lorazepam. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sodium oxybate
lorazepam, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- sufentanil SL
sufentanil SL, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- valerian
valerian and lorazepam both increase sedation. Avoid or Use Alternate Drug.
Monitor Closely (206)
- acrivastine
acrivastine and lorazepam both increase sedation. Use Caution/Monitor.
- albuterol
lorazepam increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
lorazepam and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
alprazolam and lorazepam both increase sedation. Use Caution/Monitor.
- amisulpride
amisulpride and lorazepam both increase sedation. Use Caution/Monitor.
- amitriptyline
lorazepam and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
amobarbital and lorazepam both increase sedation. Use Caution/Monitor.
- amoxapine
lorazepam and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
lorazepam and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
lorazepam increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
lorazepam and aripiprazole both increase sedation. Use Caution/Monitor.
- armodafinil
lorazepam increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and lorazepam both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and lorazepam both increase sedation. Use Caution/Monitor.
- avapritinib
avapritinib and lorazepam both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and lorazepam both increase sedation. Use Caution/Monitor.
- baclofen
lorazepam and baclofen both increase sedation. Use Caution/Monitor.
- belladonna and opium
lorazepam and belladonna and opium both increase sedation. Use Caution/Monitor.
- benperidol
lorazepam and benperidol both increase sedation. Use Caution/Monitor.
- benzphetamine
lorazepam increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, lorazepam. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and lorazepam both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and lorazepam both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and lorazepam both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and lorazepam both increase sedation. Use Caution/Monitor.
- buprenorphine
lorazepam and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
lorazepam and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
lorazepam increases toxicity of buprenorphine subdermal implant by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists. There have been postmarketing reports of coma and death with coadministration of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection. If a benzodiazepine must be used for an indication other than seizures, lower the benzodiazepine initial dose and cautiously titrate to clinical response.
- buprenorphine, long-acting injection
lorazepam increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.
- butabarbital
butabarbital and lorazepam both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and lorazepam both increase sedation. Use Caution/Monitor.
- butorphanol
lorazepam and butorphanol both increase sedation. Use Caution/Monitor.
- caffeine
lorazepam increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cannabidiol
cannabidiol will increase the level or effect of lorazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit UGT2B7 activity. Consider reducing the dose when concomitantly using UGT2B7 substrates.
- carbinoxamine
carbinoxamine and lorazepam both increase sedation. Use Caution/Monitor.
- carisoprodol
lorazepam and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, lorazepam. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
lorazepam and chloral hydrate both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and lorazepam both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.
- chlorpromazine
lorazepam and chlorpromazine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
lorazepam and chlorzoxazone both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and lorazepam both increase sedation. Use Caution/Monitor.
- clemastine
clemastine and lorazepam both increase sedation. Use Caution/Monitor.
- clobazam
lorazepam, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
lorazepam and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
clonazepam and lorazepam both increase sedation. Use Caution/Monitor.
- clonidine
clonidine, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.
- clorazepate
clorazepate and lorazepam both increase sedation. Use Caution/Monitor.
- clozapine
lorazepam and clozapine both increase sedation. Use Caution/Monitor.
lorazepam, clozapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible risk of cardiorespiratory collapse. - codeine
lorazepam and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
cyclizine and lorazepam both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
lorazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and lorazepam both increase sedation. Use Caution/Monitor.
- dantrolene
lorazepam and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
lorazepam and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desflurane
desflurane and lorazepam both increase sedation. Use Caution/Monitor.
- desipramine
lorazepam and desipramine both increase sedation. Use Caution/Monitor.
- deutetrabenazine
lorazepam and deutetrabenazine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
dexchlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.
- dexfenfluramine
lorazepam increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
lorazepam and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
lorazepam increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
lorazepam increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
lorazepam and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
lorazepam and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and lorazepam both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- dichlorphenamide
dichlorphenamide, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- diethylpropion
lorazepam increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and lorazepam both increase sedation. Use Caution/Monitor.
- difenoxin hcl
lorazepam and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and lorazepam both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and lorazepam both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
lorazepam and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
lorazepam and dipipanone both increase sedation. Use Caution/Monitor.
- dobutamine
lorazepam increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopamine
lorazepam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
lorazepam increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
lorazepam and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
lorazepam and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
lorazepam and doxylamine both increase sedation. Use Caution/Monitor.
- droperidol
lorazepam and droperidol both increase sedation. Use Caution/Monitor.
- ephedrine
lorazepam increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
lorazepam increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
lorazepam increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, lorazepam. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
estazolam and lorazepam both increase sedation. Use Caution/Monitor.
- ethanol
lorazepam and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and lorazepam both increase sedation. Use Caution/Monitor.
- fenfluramine
lorazepam increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- flibanserin
lorazepam and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.
- fluphenazine
lorazepam and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
flurazepam and lorazepam both increase sedation. Use Caution/Monitor.
- formoterol
lorazepam increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- gabapentin
gabapentin, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
lorazepam and ganaxolone both increase sedation. Use Caution/Monitor.
- haloperidol
lorazepam and haloperidol both increase sedation. Use Caution/Monitor.
- hyaluronidase
hyaluronidase, lorazepam. Other (see comment). Use Caution/Monitor. Comment: Drug combination has been found to be incompatible.
- hydromorphone
lorazepam and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and lorazepam both increase sedation. Use Caution/Monitor.
- iloperidone
lorazepam and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
lorazepam and imipramine both increase sedation. Use Caution/Monitor.
- isoproterenol
lorazepam increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketamine
ketamine and lorazepam both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
lorazepam and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, lorazepam. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, lorazepam. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
lorazepam increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levorphanol
lorazepam and levorphanol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
lorazepam increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
lorazepam and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
lorazepam and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
loprazolam and lorazepam both increase sedation. Use Caution/Monitor.
- lormetazepam
lorazepam and lormetazepam both increase sedation. Use Caution/Monitor.
- loxapine
lorazepam and loxapine both increase sedation. Use Caution/Monitor.
lorazepam, loxapine. Mechanism: unknown. Use Caution/Monitor. Risk of resp. depression, hypotension. - loxapine inhaled
lorazepam and loxapine inhaled both increase sedation. Use Caution/Monitor.
lorazepam, loxapine inhaled. Mechanism: unknown. Use Caution/Monitor. Risk of resp. depression, hypotension. - lurasidone
lurasidone, lorazepam. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
lorazepam and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
lorazepam and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
lorazepam and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
lorazepam and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
lorazepam and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
lorazepam increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
lorazepam and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
lorazepam and methadone both increase sedation. Use Caution/Monitor.
- methamphetamine
lorazepam increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
lorazepam and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
lorazepam increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methylphenidate transdermal
methylphenidate transdermal will increase the level or effect of lorazepam by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.
- midazolam
lorazepam and midazolam both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
lorazepam increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mirtazapine
lorazepam and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
lorazepam increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
lorazepam and morphine both increase sedation. Use Caution/Monitor.
- motherwort
lorazepam and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
lorazepam and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
lorazepam and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
lorazepam and nalbuphine both increase sedation. Use Caution/Monitor.
- norepinephrine
lorazepam increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
lorazepam and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
lorazepam and olanzapine both increase sedation. Use Caution/Monitor.
- oliceridine
oliceridine, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- opium tincture
lorazepam and opium tincture both increase sedation. Use Caution/Monitor.
- orlistat
orlistat decreases levels of lorazepam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions.
- orphenadrine
lorazepam and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
lorazepam and oxazepam both increase sedation. Use Caution/Monitor.
- oxycodone
lorazepam and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
lorazepam and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
lorazepam and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
lorazepam and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
lorazepam and papaverine both increase sedation. Use Caution/Monitor.
- pentazocine
lorazepam and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and lorazepam both increase sedation. Use Caution/Monitor.
- perampanel
perampanel and lorazepam both increase sedation. Use Caution/Monitor.
- perphenazine
lorazepam and perphenazine both increase sedation. Use Caution/Monitor.
- phendimetrazine
lorazepam increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital and lorazepam both increase sedation. Use Caution/Monitor.
- phentermine
lorazepam increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
lorazepam increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
lorazepam increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
lorazepam and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
lorazepam and pimozide both increase sedation. Use Caution/Monitor.
- pirbuterol
lorazepam increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pregabalin
pregabalin, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
primidone and lorazepam both increase sedation. Use Caution/Monitor.
- prochlorperazine
lorazepam and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
promethazine and lorazepam both increase sedation. Use Caution/Monitor.
- propofol
propofol and lorazepam both increase sedation. Use Caution/Monitor.
- propylhexedrine
lorazepam increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
lorazepam and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
lorazepam and quazepam both increase sedation. Use Caution/Monitor.
- quetiapine
lorazepam and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
lorazepam and ramelteon both increase sedation. Use Caution/Monitor.
- remimazolam
remimazolam, lorazepam. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- risperidone
lorazepam and risperidone both increase sedation. Use Caution/Monitor.
- salmeterol
lorazepam increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scullcap
lorazepam and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and lorazepam both increase sedation. Use Caution/Monitor.
- sevelamer
sevelamer decreases levels of lorazepam by increasing elimination. Use Caution/Monitor.
- sevoflurane
sevoflurane and lorazepam both increase sedation. Use Caution/Monitor.
- shepherd's purse
lorazepam and shepherd's purse both increase sedation. Use Caution/Monitor.
- stiripentol
stiripentol, lorazepam. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sufentanil
lorazepam and sufentanil both increase sedation. Use Caution/Monitor.
- suvorexant
suvorexant and lorazepam both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary
- tapentadol
lorazepam and tapentadol both increase sedation. Use Caution/Monitor.
- teduglutide
teduglutide increases levels of lorazepam by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.
- temazepam
lorazepam and temazepam both increase sedation. Use Caution/Monitor.
- terbutaline
lorazepam increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
lorazepam and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
lorazepam and thiothixene both increase sedation. Use Caution/Monitor.
- topiramate
lorazepam and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
lorazepam and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
lorazepam and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
lorazepam and triazolam both increase sedation. Use Caution/Monitor.
- triclofos
lorazepam and triclofos both increase sedation. Use Caution/Monitor.
- trifluoperazine
lorazepam and trifluoperazine both increase sedation. Use Caution/Monitor.
- trimipramine
lorazepam and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
triprolidine and lorazepam both increase sedation. Use Caution/Monitor.
- xylometazoline
lorazepam increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
lorazepam increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
lorazepam and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
lorazepam and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
lorazepam and zotepine both increase sedation. Use Caution/Monitor.
Minor (31)
- acetaminophen
lorazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- acetaminophen IV
lorazepam decreases levels of acetaminophen IV by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- acetaminophen rectal
lorazepam decreases levels of acetaminophen rectal by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- atracurium
lorazepam decreases effects of atracurium by pharmacodynamic antagonism. Minor/Significance Unknown.
- biotin
lorazepam decreases levels of biotin by unspecified interaction mechanism. Minor/Significance Unknown. Biotin supplementation may be necessary.
- brimonidine
brimonidine increases effects of lorazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- cisatracurium
lorazepam decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown.
- cyanocobalamin
lorazepam decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- dexmethylphenidate
dexmethylphenidate increases effects of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- esomeprazole
esomeprazole increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- eucalyptus
lorazepam and eucalyptus both increase sedation. Minor/Significance Unknown.
- fleroxacin
fleroxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- gemifloxacin
gemifloxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- green tea
green tea decreases effects of lorazepam by pharmacodynamic antagonism. Minor/Significance Unknown. Caffeine component of green tea may decrease sedative effects of benzodiazepines.
- levocarnitine
lorazepam decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown.
- levofloxacin
levofloxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- moxifloxacin
moxifloxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- ofloxacin
ofloxacin increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- omeprazole
omeprazole increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- onabotulinumtoxinA
lorazepam decreases effects of onabotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown.
- pancuronium
lorazepam decreases effects of pancuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- pyrimethamine
lorazepam, pyrimethamine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hepatotoxicity.
- rapacuronium
lorazepam decreases effects of rapacuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- rifabutin
rifabutin decreases levels of lorazepam by increasing metabolism. Minor/Significance Unknown.
- rocuronium
lorazepam decreases effects of rocuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- sage
lorazepam and sage both increase sedation. Minor/Significance Unknown.
sage decreases effects of lorazepam by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction; some species of sage may cause convulsions. - serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate increases effects of lorazepam by decreasing metabolism. Minor/Significance Unknown.
- succinylcholine
lorazepam decreases effects of succinylcholine by pharmacodynamic antagonism. Minor/Significance Unknown.
- vecuronium
lorazepam decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- vinpocetine
lorazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- zolpidem
zolpidem, lorazepam. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
Adverse Effects
Frequency Not Defined
Sedation
Dizziness
Unsteadiness
Weakness
Fatigue
Drowsiness
Amnesia
Confusion
Disorientation
Depression
Suicidal ideation/attempt
Vertigo
Ataxia
Sleep apnea
Asthenia
Extrapyramidal symptoms
Respiratory depression
Tremor
Convulsions/seizures
Visual disturbances
Dysarthria
Hypotension
Blood dyscrasias
Change in libido
Impotence
Jaundice
Increased bilirubin
Increased liver transaminases
Increase in ALP
Hypersensitivity reactions
Nausea
Constipation
Change in appetite
Paradoxical reactions (anxiety, excitation, agitation, hostility, aggression, rage)
Warnings
Black Box Warnings
Risks From Concomitant Use With Opioids
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death
- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate
- Limit dosages and durations to the minimum required
- Follow patients for signs and symptoms of respiratory depression and sedation
Addiction, abuse, and misuse
- On September 2020, FDA addressed serious risks of benzodiazepine addiction, abuse, and misuse, which can lead to overdose and death
- Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes; before prescribing and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction
- Physical dependence can occur when taken steadily for several days to weeks, even as prescribed
- Risks of dependence and withdrawal increase with longer treatment duration and higher daily dose; although injection is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, including seizures, which can be life-threatening; use gradual taper when discontinuing therapy to reduce withdrawal reactions risk
- Assess each patient’s risk prior to prescribing and monitor regularly for the development of these conditions
Contraindications
Documented hypersensitivity
Acute narrow angle glaucoma
Intra-arterial administration
Severe respiratory depression
Sleep apnea
Use of injectable dosage form in premature infants (contains benzyl alcohol)
Cautions
Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death (see BBW)
Advise both patients and caregivers about the risks of respiratory depression and sedation when lorazepam is used with opioids; advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined
Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression
Not recommended for use in patients with primary depressive disorder or psychosis
Injection contains benzyl alcohol associated with potentially fatal "gasping syndrome" in neonates and an increased incidence of kernicterus, particularly in small preterm infants; if patient requires more than recommended dosages or other medications containing this preservative, practitioner must consider daily metabolic load of benzyl alcohol from combined sources
Prolonged use may lead to physical and psychological dependence especially in patients with history of alcohol or drug abuse; risk of dependence is decreased with short-term treatment (eg, 2-4 weeks); evaluate need for continued treatment prior to extending therapy duration
Use of drug, particularly in patients at elevated risk, necessitates counseling about risks and proper use of drug along with monitoring for signs and symptoms of abuse, misuse, and addiction; do not exceed recommended dosing frequency
Avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (eg, opioid analgesics, stimulants); advise patients on proper disposal of unused drug; if a substance use disorder is suspected, evaluate patient and institute (or refer them for) early treatment, as appropriate
For patients using treated more frequently than recommended, to reduce risk of withdrawal reactions, use a gradual taper to discontinue therapy (a patient-specific plan should be used to taper the dose)
Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use
In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months
Use caution in patients with history of suicide attempt or drug abuse
Do not withdraw abruptly after prolonged use; terminate dosage gradually
Use caution in patients with impaired gag reflex
May cause CNS depression, impairing physical and mental abilities; caution patients to not operate dangerous machinery or motor vehicles
Anterograde amnesia reported with use
Use caution in patients with respiratory disease, including COPD or sleep apnea
Hyperactive or aggressive behavior and other paradoxical reactions reported with use
Caution patients that tolerance for alcohol and other CNS depressants will be diminished
General anesthetics and sedation drugs in young children and pregnant women
-
Brain development
- Published animal studies demonstrate that administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in developing brain and result in long-term cognitive deficits when used for longer than 3 hours; repeated exposure may also result in negative effects on fetal or young children’s brain development
- Caution with use during surgeries or procedures in children younger than 3 yr or in pregnant women during their third trimester
- Assess the risk:benefit ratio in these populations, especially for prolonged procedures (ie, >3 hr) or multiple procedures
Pregnancy & Lactation
Pregnancy
There is a pregnancy registry that monitors pregnancy outcomes in woman exposed to psychiatric medications; healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medication’s at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal; available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects
Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates; monitor neonates exposed to this medication during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems
Monitor neonates exposed to therapy during pregnancy for signs of withdrawal; manage these neonates accordingly
Advise pregnant females who are administered this medication late in pregnancy that therapy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns; instruct patients to inform their healthcare provider if they are pregnant
There are insufficient data regarding obstetrical safety of parenteral lorazepam, including use in cesarean section; such use, therefore, is not recommended
Lactation
This drug is present in breast milk; there are reports of sedation. poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk; effects of this drug on milk production are unknown; developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition
Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed; instruct breastfeeding patients who are administered this therapy to monitor infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Sedative hypnotic with short onset of effects and relatively long half-life; by increasing the action of gamma-aminobutyric acid (GABA), which is a major inhibitory neurotransmitter in the brain, lorazepam may depress all levels of the CNS, including limbic and reticular formation
Absorption
Bioavailability: 90%
Onset: 1-3 min (IV in sedation); 15-30 min (IM in hypnosis)
Duration: Up to 8 hr
Peak plasma time: 2 hr (tablets); 14 hr (capsules); <3 hr (IM)
Peak plasma concentration: 41 ng/mL (tablets); 25 ng/mL (capsules
Trough concentration: 29 ng/mL (tablets); 25 ng/mL (capsules)
AUC: 765 ng⋅h/mL (tablets); 695 ng⋅h/mL (capsules)
Steady-state: 5 days (capsules)
Distribution
Protein bound: 85-93%
Vd: 1.9 L/kg (adolescents); 1.3 L/kg (adults); 0.78 L/kg (neonates); 177 L (capsules)
Metabolism
Metabolites: Inactive
Undergoes glucuronic acid conjugation
Elimination
Half-life: 18 hr (children 2-12 years); 42 hr (neonates); 28 hr (adolescents); 18 hr (end stage renal disease); 12 hr (tablets, adults); 20.2 hr (capsules, adults)
Excretion: Urine (88% mainly as inactive metabolites); feces (7%)
Administration
IV Incompatibilities
Additive: Buprenorphine, dexamethasone sodium phosphate with diphenhydramine and metoclopramide
Syringe: Sufentanil
Y-site: Aldesleukin, aztreonam, floxacillin, foscarnet, idarubicin, imipenem/cilastatin, omeprazole, ondansetron, sargramostim, sufentanil
IV Preparation
Parenteral admixture stable for 24 hr at room temp (25°C)
Usually given IVP
Standard IVP dilution: dilute immediately before use with equal amount of NS or SWI
Usual dilution for continuous infusion: 1 mg in 100 mL D5W
Discard if discoloration or precipitate
IV/IM Administration
IM administration
- Administer deep into muscle mass
IV administration
- Prior to use, dilute injection solution with an equal amount of compatible diluent (D5W, NS, SWFI)
- Administer IV injection slowly, directly into a vein or into tubing of a free-flowing, compatible IV infusion (eg, NS, D5W), at no more than 2 mg/min
- Validate patent venous catheter with repeated aspiration during infusion to visualize venous blood return
- Inadvertent intra-arterial injection may produce arteriospasm resulting in gangrene, potentially requiring amputation
- Rapid IV infusion may result in apnea, bradycardia, hypotension, cardiac arrest
- Continuous infusion solutions should have an in-line filter and should be checked frequently for possible precipitation
- Emergency resuscitative equipment should be available when administering IV
Oral Administration
Capsules
- May take with or without food
- Swallow whole, do not crush or chew
-
Unable to swallow capsule
- Capsule may be opened and entire contents sprinkled onto a tablespoon of applesauce
- Swallow mixture without chewing
- Swallow within 2 hours of mixing; do not store mixture for future use
- Drink a glass of water after swallowing mixture
Discontinuation
- Gradually taper dose to reduce risk of withdrawal reactions
- If withdrawal reactions occur, consider pausing the taper or increasing the dosage to the previous tapered dosage level; subsequently decrease dosage more slowly
Storage
IV/IM injection: Refrigerate intact vials at 2-8°C (36-46°F) and protect contents from light
Tablets: Keep tightly closed; store at 25°C (77°F)
Oral concentrate: Store at cold temperature; refrigerate at 2-8°C (36-46°F); discard open bottle after 90 days
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Loreev XR oral - | 3 mg capsule |  | |
| Loreev XR oral - | 2 mg capsule |  | |
| Loreev XR oral - | 1 mg capsule |  | |
| Ativan injection - | 4 mg/mL vial |  | |
| Ativan injection - | 2 mg/mL vial |  | |
| Ativan injection - | 2 mg/mL vial |  | |
| Ativan injection - | 4 mg/mL vial |  | |
| Ativan injection - | 4 mg/mL vial |  | |
| Ativan injection - | 2 mg/mL vial |  | |
| Ativan oral - | 2 mg tablet |  | |
| Ativan oral - | 1 mg tablet |  | |
| Ativan oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 1 mg tablet |  | |
| lorazepam oral - | 2 mg tablet |  | |
| lorazepam oral - | 1 mg tablet |  | |
| lorazepam oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 2 mg tablet |  | |
| lorazepam oral - | 1 mg tablet |  | |
| lorazepam oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 2 mg tablet |  | |
| lorazepam oral - | 1 mg tablet |  | |
| lorazepam oral - | 2 mg tablet |  | |
| lorazepam oral - | 2 mg/mL liquid |  | |
| lorazepam oral - | 0.5 mg tablet |  | |
| lorazepam oral - | 2 mg tablet |  | |
| lorazepam oral - | 1 mg tablet |  | |
| lorazepam oral - | 2 mg/mL liquid |  | |
| lorazepam oral - | 2 mg/mL liquid |  | |
| Lorazepam Intensol oral - | 2 mg/mL liquid |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 4 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 4 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 4 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL solution |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 4 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  | |
| lorazepam injection - | 2 mg/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
lorazepam oral
LORAZEPAM - ORAL
(lor-AYE-zeh-pam)
COMMON BRAND NAME(S): Ativan
WARNING: Lorazepam has a risk for abuse and addiction, which can lead to overdose and death. Taking this medication with alcohol or other drugs that can cause drowsiness or breathing problems (especially opioid medications such as codeine, hydrocodone) may cause very serious side effects, including death. To lower your risk, your doctor should have you take the smallest dose of lorazepam that works, and take it for the shortest possible time. Be sure you know how to take lorazepam and what other drugs you should avoid taking with it. See also Drug Interactions section. Get medical help right away if any of these very serious side effects occur: slow/shallow breathing, unusual lightheadedness, severe drowsiness/dizziness, difficulty waking up.Suddenly stopping this medication may cause serious (possibly fatal) withdrawal, especially if you have used it for a long time or in high doses. To prevent withdrawal, your doctor may lower your dose slowly. Tell your doctor or pharmacist right away if you have any withdrawal symptoms such as headaches, trouble sleeping, restlessness, hallucinations/confusion, depression, nausea, or seizures. Withdrawal symptoms may sometimes last weeks to months.
USES: This medication is used to treat anxiety. Lorazepam belongs to a class of drugs known as benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
HOW TO USE: See also Warning section.Read the Medication Guide provided by your pharmacist before you start taking lorazepam and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth with or without food as directed by your doctor. The dosage is based on your medical condition, age, and response to treatment.If directed by your doctor, use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same time(s) each day.Do not suddenly stop using this drug without consulting your doctor. Some conditions may become worse when this drug is abruptly stopped. Your dose may need to be gradually decreased.When this medication is used for a long time, it may not work as well. Talk with your doctor if this medication stops working well.Though it helps many people, this medication may sometimes cause addiction. This risk may be higher if you have a substance use disorder (such as overuse of or addiction to drugs/alcohol). Take this medication exactly as prescribed to lower the risk of addiction. Ask your doctor or pharmacist for more details.Tell your doctor if your condition lasts or gets worse.
SIDE EFFECTS: See also Warning section.Drowsiness, dizziness, loss of coordination, headache, nausea, blurred vision, change in sexual interest/ability, constipation, heartburn, or change in appetite may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as hallucinations, depression, thoughts of suicide), trouble speaking, vision changes, unusual weakness, trouble walking, memory problems, signs of infection (such as sore throat that doesn't go away, fever).Get medical help right away if you have any very serious side effects, including: yellowing eyes or skin, seizures, slow/shallow breathing.This medication can rarely have the opposite of its usual calming effect. Symptoms of this opposite effect may include agitation, irritability, violent behavior, confusion, restlessness, excitement, and talking more than normal. Tell your doctor right away if you notice any of these effects.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking lorazepam, tell your doctor or pharmacist if you are allergic to it; or to other benzodiazepines (such as alprazolam, clonazepam, diazepam); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, glaucoma, lung/breathing problems (such as sleep apnea), mental/mood disorders (such as depression, psychosis), personal or family history of a substance use disorder (such as overuse of or addiction to drugs/alcohol).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially loss of coordination and drowsiness. Loss of coordination and drowsiness may increase the risk of falling. Also, lorazepam may have the opposite of its usual calming effect in older adults (see also Side Effects section).This drug may have the opposite of its usual calming effect in children, causing restlessness, shaking, or mental/mood changes (such as agitation, hallucinations).Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using lorazepam. Lorazepam may harm an unborn baby. Newborn babies of mothers who use this medication late in pregnancy may have symptoms such as slow/shallow breathing, nonstop crying, shaking, or trouble feeding. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.This drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also Warning section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: clozapine, kava, sodium oxybate (also known as gamma hydroxybutyrate or GHB).The risk of serious side effects (such as slow/shallow breathing, severe drowsiness/dizziness) may be increased if this medication is taken with other products that may also cause drowsiness or breathing problems. Tell your doctor or pharmacist if you are taking other products such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), other drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include confusion, slow reflexes, clumsiness, deep sleep, and loss of consciousness.
NOTES: Lifestyle changes such as starting a stress reduction program may increase the effectiveness of this medication. Talk to your doctor or pharmacist about lifestyle changes that might benefit you.Do not share this medication with others. Sharing it is against the law.Lab and/or medical tests (such as blood counts, liver function) should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose and are taking more than 1 dose daily, do not take it if it is almost time for the next dose. Instead, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up. If you take it once daily at bedtime and miss a dose, do not take it the following morning. Call your doctor to find out what to do.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
